$1.05
-0.01 (-0.94%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PHIO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 3 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Intratumoral PH-762 for Cutaneous CarcinomaNCT06014086Adverse EventsOpen-label · Treatment | Phase 1 | Active, not recruiting | Drug: PH-762 | Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin | 30 | 2025-12-29actual | 2026-02-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19